Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus

TY - JOUR

T1 - Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2007/5/28

Y1 - 2007/5/28

N2 - GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.

AB - GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.

M3 - Review

SN - 0041-5782

VL - 169

SP - 2095

EP - 2099

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 22

ER -